February 3, 2017 / 6:31 AM / in 9 months

BRIEF-Seikagaku initiates phase III study of SI-613

Feb 3 (Reuters) - Seikagaku Corp :

* Says co announces the start of Phase III study of SI-613, a joint improving agent indicated for treatment of osteoarthritis, in Japan

Source text in Japanese: goo.gl/wLpH3O

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below